fbpx

Next Science Ltd

NXS.AX

$0.09

Closing

▲7.69%

1D

▼-58.82%

YTD

NXS

BBG00NKWLX00

Exchange

Sector

Market cap

$26.63M

Volume

45,534

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$26.63M

Analysts' Rating

BUY

Price Target (Mean)

0.22

Total Analysts

0

P/E

Operating Margin

-52.17%

Beta

1.92

Revenue Growth

11.13%

52 week high

$0.33

52 week low

$0.07

Div. Yield

%

EPS Growth

0.00

Company Profile

Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.